Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738614) titled 'A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight' on July 28.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Obesity
Overweight
Intervention:
Drug: Eloralintide
Drug: Placebo
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: July 2026
Target Sample Size: 56
Countries of Recruitment:
United States
Singapore
United States
To know more, visit https://clinicaltrials.gov/st...